首页 | 本学科首页   官方微博 | 高级检索  
     


Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study
Authors:Thomas Berg  Pietro Andreone  Stanislas Pol  Stuart Roberts  Zobair Younossi  Moises Diago  Eric J. Lawitz  Roberto Focaccia  Graham R. Foster  Andrzej Horban  Isabelle Lonjon‐Domanec  Ralph DeMasi  Gaston Picchio  Donghan Luo  Sandra De Meyer  Stefan Zeuzem
Affiliation:1. Universit?tsklinikum Leipzig, Sektion Hepatologie, Klinik für Gastroenterologie und Rheumatologie, Leipzig, Germany;2. Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy;3. Université Paris Descartes, INSERM Unité 1016, and Assistance Publique–H?pitaux de Paris, Cochin Hospital, Paris, France;4. Department of Gastroenterology, Alfred Hospital, Melbourne, Victoria, Australia;5. Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, Virginia, USA;6. Hospital General de Valencia, Valencia, Spain;7. Alamo Medical Research, San Antonio, Texas, USA;8. Emilio Ribas Institute of Infectious Diseases, S?o Paulo, Brazil;9. Queen Marys University of London, Institute of Cell and Molecular Science, London, UK;10. Medical University of Warsaw, Wolska, Warsaw, Poland;11. Janssen, Paris, France;12. Janssen Research and Development LLC, Titusville, New Jersey, USA;13. Janssen Infectious Diseases BVBA, Beerse, Belgium;14. Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany
Abstract:
Keywords:   HCV        LDL     predictors     REALIZE     response  telaprevir
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号